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Abstract: Neonatal abstinence syndrome (NAS) is a postnatal withdrawal syndrome among neonates
born to mothers with drug dependence disorders. NAS poses a significant public health challenge
nationally, with a six-fold increase in incidence (1.2 to 6.7 per 1000 hospital births/year) from
2000–2016. Besides national data, it is critical to quantify NAS at the state-level to identify target areas
for prevention. The objectives of this study were to ascertain statewide burden, including county
and regional distribution of NAS in Nevada during 2016–2018, and to investigate potential factors
associated with NAS. This study utilized hospital administrative data, and a total of 100,845 inpatient
pediatric discharges were examined to identify NAS cases. Statistical analyses included estimation
of crude incidence rates per 1000 hospital births and multilevel logistic regression modeling. NAS
incidence in Nevada decreased slightly from 8.6 to 7.7 per 1000 hospital births between 2016 and
2018, but the overall incidence of 8 was substantially higher than earlier estimates (4.8/1000 hospital
births) reported for 2013. Incidence was disproportionately higher among white newborns (12,
95% CI 11.0,13.0) and Medicaid enrollees (13.2, 95% CI 11.0,15.0). Southern Nevada had the highest
incidence rate of 8.2 per 1000 hospital births. Nearly 75% of NAS cases were residents of Clark County.
Incidence rates of NAS parallel the growing opioid prescription rates in Nevada and highlight the
need for adopting opioid control prescribing practices to combat this drug epidemic. These findings
might help in designing and evaluating state- and system-level interventions introduced to combat
the opioid epidemic.
Keywords: neonatal abstinence syndrome; neonatal opioid withdrawal syndrome; opioid use disor-
der; Nevada; multilevel modelling
1. Introduction
Neonatal abstinence syndrome (NAS) or neonatal opioid withdrawal syndrome
(NOWS) is a constellation of withdrawal symptoms, manifested immediately after birth
among babies born to mothers with drug dependence, following abrupt discontinuation of
in-utero exposure to the drugs, including illegal or prescription opioids [1,2]. The risk of
NAS also exists for critically ill or hospitalized infants who develop physical dependence
on medications used for achieving analgesia and sedation [1]. The latter is called neonatal
iatrogenic withdrawal or therapeutic NAS, which occurs secondary to therapeutic exposure
of the drugs used in the neonatal intensive care units (NICU) [1–3]. NAS and neonatal
iatrogenic withdrawal present a similar spectrum of symptoms, mainly affecting the ner-
vous and gastrointestinal systems [3–5]. Symptoms of NAS/NOWS include wakefulness,
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irritability (high-pitched cry), tremors, hypertonic muscles, diarrhea, regurgitation (poor
sucking reflex), difficulty breathing, and impaired weight gain [4–6]. NAS might result
in long-term consequences, such as cognitive deficit and behavioral problems [7]. Death
might also occur in the absence of appropriate treatment [7]. NAS results in approximately
75–95% of cases, following maternal drug use, which also increased significantly over
the past few decades [1,8]. Between 1998–2011, the prevalence of maternal opioid use in
the U.S. increased by 127% [9]. From 2000–2009, the antepartum use of opiates increased
from 1.19 to 5.63 per 1000 births/year in the United States [8]. Consequently, there were
21,732 infants reported to be born with NAS in 2012 [10].
The incidence of NAS increased approximately 6-fold (1.20 to 6.7 per 1000 hospi-
tal births/year; 450%) from 2000–2016 [8–11]. Geographic variations of NAS incidence
were also reported with the East South-Central region showing an incidence of 16.2 per
1000 hospital births, compared to the West South-Central region, with an incidence rate of
2.6 per 1000 hospital births [11]. At the state level, significant variations in NOWS incidence
were also observed with an incidence as low as 0.7 cases per 1000 births in Hawaii, com-
pared to an incidence of 33.4 cases per 1000 hospital births in West Virginia [11,12]. These
state-wide variations might be due to differences in opioid prescribing rates and prevalence
of opioid use disorder (OUD) among pregnant women and use of illicit substances [13].
For instance, the higher incidence of NAS in West Virginia can be partly explained by its
higher opioid pain relievers (OPR) prescribing rates (137.6 prescriptions per 100 persons
in 2012) and elevated incidence rates (30 cases per 1000 delivery hospitalizations/year in
2014) of OUD among reproductive-aged and pregnant women [11–14].
Similar trends also persist in other states. For instance, in Nevada the prevalence
of OUD increased from 0.6 to 4.5 from 2002 to 2014 [13]. Nevada ranks 15th in prescrib-
ing OPRs and had a consistently higher OPR prescribing rate than the national figures
(94.1 prescriptions/100 persons in Nevada vs. 82.5 OPR prescriptions/100 persons, na-
tionally) in 2012 [14]. Correspondingly, the incidence of NAS in Nevada increased from
1.1 cases per 1000 births in 2003 to 4.8 cases per 1000 births in 2013 [12]. Our study ad-
vanced this literature in two ways. First, previous national and statewide estimates of
NAS were based on the International Classification of Diseases-9 (ICD-9) coding with
limited ability to differentiate NAS (secondary to maternal drug abuse) and therapeutic
NAS (iatrogenic withdrawal). These estimates were provided after excluding the cases of
presumed iatrogenic or therapeutic exposures [8,10] (diagnostic codes 765.00–765.05, 770.7,
772.10–772.14, 777.50–777.53, 777.6, and 779.7). Effective October 2015, the ICD-9-CM was
replaced by the ICD-10-CM coding system, which offers better specificity to make a clear
distinction across the two kinds of NAS. Additionally, assessment of NAS in Nevada is
limited due to a lack of granularity at the county and regional levels. This study provides
the most recent, precise, and comprehensive incidence estimates (including countywide
data), which are important to the formulation of public health plans and allocation of
health resources to improve neonatal health outcomes in Nevada. Second, we know little
as to how the risk of NAS varies with demography, clinical characteristics, and hospital
setting. This study explores potential patient and system-level predictors associated with
NAS, which could help state and local government to more precisely tailor and target their
current NAS prevention efforts.
2. Materials and Methods
2.1. Study Design and Data Source
This study was geographically defined and employed a statewide, nested (within
hospitals’ cluster), multiple cross-sectional analysis using hospital admission discharge
data extracted from a de-identified state administrative database, provided by the Center
for Health Information Analysis for Nevada (CHIA) [15]. As the study used de-identified
data, it was considered an ‘excluded’ study (Protocol ID: 1538606) as per the Institutional
Review Board criteria, according to federal regulations. Data were summarized in tables
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and graphs, and aggregated population-based estimates were calculated if sample sizes
were adequate; any sample with n < 10 was suppressed to preserve confidentiality.
2.2. Sample Selection
The population included all singleton newborn hospital (inpatient) discharge records
from Nevada for the years 2016–2018. Infants with ICD-10-CM code P96.1 appearing in
any diagnostic field in the hospital discharge database were included. Suspected cases of
NAS, without ICD-10-CM code P96.1 and with codes P0414, P0417, and P041A were also
searched (as per the Council of State and Territorial Epidemiologists definition of NAS) [16].
The following records were excluded—infants with drug withdrawal following therapeutic
drug use (ICD-CM-P96.2) and newborns affected by reactions and intoxications from
maternal opiates and tranquilizers used during labor and delivery (P04.0). As a reference
group (non-NAS/healthy), uncomplicated births were identified using the ICD-10 code
Z38.00 assigned to “single liveborn infant.”
2.3. Statistical Analysis
A secondary analysis of hospital administrative data was conducted. The unit of anal-
ysis was the newborn discharge/admission (in-patient) record. All statistical procedures
utilized the SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). The incidence rate
was determined arithmetically by dividing NAS-related newborn hospitalizations by the
total number of newborn hospitalizations (with conversion to number per 1000). Overall
rates (with 95% confidence intervals) are presented by demographic variables, including
sex, payer source, median household income, and patient location. The median household
income was approximated to the patient zip code using the most recent (2019) estimates
of the American Community Survey [17]. The classification criteria (according to 2019
estimates) for income quartiles (Q1–Q4) was obtained from the Health Cost and Utilization
Project (HCUP) database [18]. Patient location was categorized into large central metropoli-
tan, medium metro, small metro, and rural (including micropolitan and noncore) according
to the 2013 new county-level scheme developed by the National Center for Health Statistics
(NCHS) [19]. Primary payer information was categorized as public (Medicaid), private,
and uninsured (including self-pay and no charge).
For investigating potential predictors, the primary outcome of interest was NAS
(dependent variable), which was re-coded into a binary variable indicating presence
(NAS = 1) or absence of NAS (NAS = 0) for the multilevel logistic regression model,
to identify the factors between NAS and non-NAS births. The multilevel (2-level) logistic
regression analysis was conducted using the GLIMMIX procedure to account for clustering
of patients within higher-level units (i.e., hospitals). Hospital-level factors, such as hospital
academic status (teaching hospital vs. non-teaching hospital), hospital location (rural vs.
urban), and hospital bed size (≤100, 101–299, ≥300) were examined as factors of NAS.
The categorization of hospital factors was adapted from previous studies [20,21]. In the
examination of potential multilevel models, three models were built to find the best fit.
The first was the null model (i.e., without any patient or hospital-related variables). This
incorporated only hospital-specific random effects to model between-hospital variation
in terms of NAS status [20]. The intraclass correlation coefficient (ICC) from the first
model quantified the hospital-clustering effect [20,22,23]. The second model included all
patient-related (level 1) variables as fixed effects, and only included the hospital-specific
random intercept to examine the relationship between these variables and the incidence of
NAS. A correlation matrix for all independent (level 1) variables included in the second
model was calculated and examined for potential multicollinearity [24]. Upon detection of
significant correlation between two variables, only one variable was included in the model.
The third model included both patient and hospital factors in addition to hospital-specific
random effects, and risk estimates were presented by the odds ratio [22,23].
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3. Results
The study population consisted of 100,845 newborns discharged from 18 Nevada
hospitals from 2016 to 2018. The number of newborns treated per hospital ranged from 224
to 15,542, with a median of 3762 (25th–75th percentile: 1466–9121).
3.1. Incidence
During the study period (2016–2018), NAS occurred among 796 (0.8%) inpatient
pediatric discharges in Nevada. In terms of yearly variations, incidence of NAS decreased
slightly from 8.6 (95% CI 8.0,9.0) to 7.7 per 1000 hospital births (95% CI 7.0,9.0) between
2016 and 2018, but the overall incidence (8.0; 95% CI 7.0,9.0) was substantially higher
(1.7 times) than earlier estimates (4.8/1000 hospital births) reported for 2013. The overall
NAS incidence varied across different regions, with Southern Nevada showing the highest
incidence rate of 8.2 (95% CI 8.0,9.0) per 1000 hospital births, compared to other regions
(northern, Washoe, and rural). In 2016, 78% of NAS cases diagnosed in Nevada were
residents of Clark County (230 NAS cases in Clark vs. 292 in Nevada). From 2016 to 2018,
the incidence rates declined slightly in Clark County, whereas Washoe County showed
increasing trends. In 2016, the incidence of NAS in Henderson was the highest among other
Nevada cities and then decreased by nearly 33% in the following two years. In the most
recent study year (2018), Henderson still had the highest incidence rate among Nevada
cities (i.e., 9.7 per 1000 hospital births) followed by Reno, North Las Vegas, and Las Vegas
(Table 1).
Among different demographic groups, the overall incidence of NAS was the highest
among white newborns, occurring at a rate of 12.0 per 1000 hospital births (95% CI 11.0,
13.0). The incidence of NAS among white infants decreased after 2016; however, a trend
reversal was observed among Asian Pacific Islander (API) infants. The incidence of NAS
increased from 0.9 to 3.8 per 1000 newborn hospitalizations among API infants, from 2016
to 2018. There were no differences in the overall incidence rates by gender. NAS rates
also varied by income zip quartile, with infants born in the areas of the lowest quartile
with a median household income of ≤$47,699 showing the highest overall incidence of
NAS of 12.8 (95% CI 8.0,13.0) per 1000 hospital births. In terms of urbanization of level of
residence, the NAS incidence rate was highest in large central metropolitan areas and lower
but comparable among rural and small/medium metropolitan areas. Rates differed by
expected payer source, with Medicaid-insured births showing the highest NAS incidence
of 13.2 (95% CI 11.0,15.0) per 1000 hospital births, and 77.4% (616 out of 796) of NAS births
financed by Nevada Medicaid (Table 2).
3.2. Predictors
In the model building process, model 3 (with level-1 & level-2 factors) appeared to be
the best fit, given the progressively decreasing values of Akaike and Bayesian information
criteria [24], as progression occurred from model 1 through model 3. In the unconditional
model, a non-zero value of intraclass coefficient (6.5%) indicated the presence of a clustering
effect of hospitals. In other words, the variability in NAS incidence attributed to the
hospitals [20,24] was minimal, leaving 93.5% of the variability to be accounted for by
patients (Table 3). In model 3, seven of the 13 patient characteristics (i.e., race, payer source,
feeding difficulty, neonatal jaundice, seizures, transient tachypnoea, and sepsis) and none
of the hospital characteristics were associated with the odds of being diagnosed with
NAS. The remaining five patient level factors (i.e., gender, low birth weight, meconium
aspiration syndrome, respiratory problems, and respiratory distress syndrome) were not
statistically significant. In terms of race, white infants were nearly 6 times more likely to
have NAS compared to black infants (OR 6.16 vs. 1.64). When examining the payer source,
Medicaid insured infants were 2.8 times (OR 2.88; 95% CI 1.2–4.2) more likely to have NAS
compared to those uninsured. Examination of comorbidities revealed that NAS infants
had higher odds of developing transient tachypnoea, seizures, neonatal jaundice, feeding
difficulties, and sepsis, compared to healthy hospital births. Finally, none of the hospital
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factors studied, including bed size, location (rural/urban), status (teaching/non-teaching),
and type (private/public) were statistically significant (Table 4).
Table 1. NAS rates per 1000 births by different Nevada geographical units, 2016–2018.
Geographical Unit
Number of NAS Cases
Rate Per 1000 Hospital Births a Overall Rate Per 1000
(95% Confidence Interval e)
2016 2017 2018 2016 2017 2018 (2016–2018)
































































































a—The rates do not include suspect cases (n < 10). The suspect case is a neonate without a billing diagnosis of ICD-10 code of P96.1 diagnosis
AND contains any diagnosis code of P0414, P0417, and P041A, indicating maternal use of opiates, sedative-hypnotics or anxiolytics within
the birth hospitalization or a hospitalization before 28 days of age; b—Southern Nevada: Clark, Esmeralda, and Nye counties; Northern
Nevada: Carson City, Churchill, Douglas, Lyon, Mineral, and Storey counties; Washoe region: Washoe county; Rural Nevada Region: Elko,
Eureka, Humboldt, Lincoln, Pershing, and White Pine counties; c—NR = Not reported due to low volume of NAS cases (n < 10); d—Other
counties: Carson City, Churchill, Douglas, Elko, Esmeralda, Humboldt, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine;
e—lower confidence limits were truncated to “0” in the event the transformed value was negative.
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Table 2. NAS rates per 1000 births by demographic, payer groups, and median income (2016–2018).
Group Criteria
Number of NAS Cases
Rate Per 1000 Hospital Births Overall Rate Per 1000
(95% Confidence Interval g)
2016 2017 2018 2016 2017 2018 (2016–2018)
Gender











































Urbanization level of residence





















































































a—Not reported due to low volume of NAS cases (n < 10); b—Large central metro: Clark; c—Medium Metro: Washoe & Storey; d—Small
metro: Carson City; e—Rural: The two categories of micropolitan (Churchill, Douglas, Elko, Eureka, Humboldt, Lyon, Nye) and noncore
(Esmeralda, Lander, Lincoln, Mineral, Pershing, White Pine) were combined into a single rural category to preserve the results when the
sample sizes were small.; f—Uninsured payer category included self-pay and no charge; g—lower confidence limits were truncated to “0”
in the event the transformed value was negative.
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Table 3. Multilevel model building process.
Model Model 1 Model 2 Model 3
Model building process
Method No predictors, just random effect for the intercept Model 1 + level-1 fixed effects a Model 2 + level-2 predictors b
Model fit statistics
AIC c 9179.62 4860.87 4792
BIC d 9181.29 4880.87 4813
Hospital clustering statistics
ICC e 0.065 (6.5%)
a—Level-1 (patient) factors: Gender, race, low birth weight, neonatal jaundice, transient tachypnoea, seizures, respiratory distress problems,
respiratory difficulties, feeding difficulties, sepsis, and meconium aspiration syndrome (MAS); b—Level-2 (hospital) factors: Hospital
academic status, hospital location (rural vs. urban), and hospital bed size (≤100, 101–299, ≥300); c—Akaike’s information criterion (AIC)
used to examine model fitness. The progressive decreasing values (from model 1 to model 3) of AIC indicate improvement in model fitness;
d—Bayesian information criterion (BIC) used to examine model fitness. The progressive decreasing values of BIC (from model 1 to model
3) indicate improvement in model fitness; e—Intraclass coefficient (ICC) was calculated manually. Formula of ICC—random intercept
variance/random intercept variance + 3.29 (3.29 is the standard logistic distribution); random intercept variance 0.2295 (model 1).
Table 4. Estimated odds ratio for multilevel logistic regression models.
Variable
Odds Ratio a (95% Confidence Interval)
Model 2 Model 3
Patient characteristics
Female Reference Reference
Male 0.97 (0.8–1.1) 0.97 (0.8–1.2)
Race
Hispanic Reference Reference
White 6.69 (5.1–8.7) 6.16 (4.7–8.1)
Black 1.73 (1.2–2.4) 1.64 (1.2–2.3)
Asian or Pacific islander 1.32 (0.8–2.2) 1.22 (0.71–2.11)
Payer
Self-pay/uninsured Reference Reference
Private 0.56 (0.4–0.8) 0.54 (0.4–0.8)
Nevada Medicaid 2.87 (2.0–4.2) 2.88 (2.0–4.2)
Comorbidities
Feeding difficulty 4.60 (3.7–5.7) 4.54 (3.6–5.7)
Neonatal Jaundice 3.30 (2.8–4.0) 3.32 (2.8–4.0)
Seizures 2.90 (1.3–6.7) 2.96 (1.3–6.9)
Transient Tachypnoea 2.50 (2.0–3.1) 2.43 (1.9–3.1)
RDS b 1.12 (0.9–1.4) 1.11 (0.9–1.4)
Sepsis 1.65 (1.2–2.3) 1.67 (1.2–2.3)
Meconium Aspiration Syndrome 1.00 (0.3–2.4) 0.98 (0.3–2.4)
Respiratory problems 0.53 (0.2–1.3) 0.53 (0.2–1.3)
Low birth weight 0.97 (0.7–1.4) 0.97 (0.7–1.4)
Hospital factors
Bed size - -
≥300 - Reference
101–299 - 0.92 (0.5–1.7)
≤100 - 0.98 (1.0–2.1)
Location
Rural - Reference
Urban - 1.37 (0.5–3.0)
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Table 4. Cont.
Variable
Odds Ratio a (95% Confidence Interval)
Model 2 Model 3
Status - -
Non-teaching - Reference
Teaching - 0.93 (0.4–1.2)
Type - -
Non-private - Reference
Private - 0.56 (0.6–1.1)
a—Odds ratios are conditional or cluster-specific measures of association or intra-cluster measures of
association [19]; b—Respiratory distress syndrome. Note: Bold font in the Model columns indicates
association.
4. Discussion
In this study of infants discharged from Nevada hospitals, we observed an incidence
rate of 8.6 per 1000 hospital births in 2016, which was nearly 23% greater than the national
rate (7.0 per 1000 hospital births) [11,12]. Prior to 2016, the incidence rate of NAS in
Nevada were slightly lower than the national rate (5.7 vs. 6.5 per 1000 hospital births in
2014). However, national estimates of NAS for the subsequent years need to be validated
if incidence of NAS in Nevada is consistently higher than the rest of the nation, after
2016. The increasing incidence of NAS might partially be attributed to the variations in
opioid prescribing rates, for instance, Nevada had a higher opioid prescribing rate of
80.7 prescriptions per 100 persons compared to 66.5 prescriptions per 100 persons in the
U.S. in 2016 [24–26]. Clark County had higher opioid prescribing rates compared to Nevada
in 2016 (78 vs. 73 prescriptions per 100 persons), which might have contributed to the
higher NAS incidence rate in Clark County (9.1/1000 vs. 8.6/1000 hospital births) [25–27].
This finding has strong implications for developing countywide (particularly Clark County)
evidence-based interventions to promote judicious prescribing practices, thereby reducing
NAS. In 2016, the Centers for Disease Control and Prevention (CDC) provided guidelines
for prescribing opioids for chronic pain management, which requires clinicians to weigh
the risks and benefits associated with opioid use before prescribing to patients [28]. It also
recommends that clinicians manage chronic pain with nonpharmacological and nonopioid
pharmacological methods, unless the expected benefits of opioid therapy outweigh the
harms associated with it [28]. If opioid pain relievers are to be prescribed, then immediate
release opioids should be preferred over extended release opioids [28]. These guidelines are
intended to improve the communication between clinicians and patients to raise awareness
about the safe and effective use of opioid analgesics.
Our study also reports a slight decrease in NAS incidence in 2017–2018. This decrease
could represent a true plateau in the number of cases or might be due to decreased opioid
prescribing rates, which dropped to 73 prescriptions per 100 persons and 55.5 prescriptions
per 100 persons in 2017 and 2018, respectively [24–26]. The parallel trend between opioid
prescribing rates and NAS is supportive of an association. These findings hint at the
beneficial downstream neonatal impacts of diminished maternal opioid prescribing and un-
derscore the continuing need of stringent regulations for preventing opioid overprescribing,
such as the use of Prescription Monitoring Programs (PMPs) or by providers. Nonetheless,
the potential of PMPs is not yet realized. Currently, 49 states (including Nevada) have
operational PMPs; however, their utilization is low [29]. Therefore, prospective studies to
assess rate of use/adoption of PMPs by providers and the effectiveness of states’ PMPs on
opioid overprescribing rates can be a crucial step in controlling the opioid epidemic and
neonatal sequelae, such as NAS. As expected, a higher NAS incidence was observed among
Nevada Medicaid beneficiaries, which is consistent with previous reports [8,12,29,30]. This
might be due to a higher prevalence of prescription opioid use among Medicaid-enrolled
women of reproductive age, as opposed to those privately insured (39.4% vs. 27.7%) [31].
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Substantial variations in NAS incidence by race also exist, with the greatest inci-
dence rates among white infants (12.0 per 1000 births) compared to black infants (5.4 per
1000 births). These racial differences in NAS incidence might be due to higher prescription
drug use among white women [30–32]. According to a recent Nevada-based study, the
rate of emergency room visits secondary to opioid, heroin, and cannabis increased among
the white population compared to other racial groups in 2016, which can help explain the
racial disparity seen in terms of NAS incidence [27]. The increasing use of opioids pain
relievers and other addictive substances among pregnant women warrants the need for
screening and education of expectant mothers, increased access to follow-up facilities, early
intervention services for high-risk mothers and infants, and for drug abuse treatment and
prevention programs aimed at improving the health outcomes of mother–infant dyads.
This study also found higher incidence rates of NAS in urban counties, as compared
to rural counties. These findings were not consistent with other nationwide studies [33,34].
Empirical evidence to explain this discordant finding is lacking; however, we believe
that the shortage of primary care physicians, and mid-level practitioners due to a lim-
ited economic base [35,36] in rural Nevada might have contributed to the reduction in
providers’ prescribed opioids and thus NAS. Additionally, the association of urbanization
and maternal substance abuse is driven by multiple complex interrelationships based on
macrolevel (availability of drugs and economic instability), microlevel (genetic vulnerabil-
ity and personality traits), and local (family) dynamics, which cannot be uncovered by a
single analysis [35–37].
4.1. Limitations
Our study has limitations that merit discussion. Primarily, the results of the study
are not generalizable to the entire U.S., and the findings are not generalizable to deliveries
occurring outside of hospitals. We suspect our county rates to be slightly underestimated
because individuals living in border counties might seek medical care from neighboring
states. In addition, a misclassification bias due to coding errors might have been introduced
because of the use of hospital administrative data for reporting conditions or diseases
in the form of billing codes. Moreover, it might be subject to underreporting because
administrative data typically report fewer cases than clinical reporting. Further, the ad-
ministration claimed that data lacked details to clinically assess NAS cases, in terms of
severity, treatment outcomes, and type of drug exposure. Lastly, due to the unavailability
of a “linkage key,” linking maternal records and neonatal records was not possible, which
restricted our ability to examine maternal risk factors.
4.2. Strengths
To our knowledge, this was the first study to examine the distribution of NAS in
Nevada, including county and city estimates. This report provides recent incidence rates
of NAS, which can serve as baseline data for regional program planning and management,
for reducing the burden of NAS in Nevada. Estimates provided by our study are expected
to have a relatively greater precision. However, direct comparisons of our findings with
estimates of prior studies should be interpreted with caution because of the transition of
the ICD-9 to ICD-10 coding system, after 2015.
5. Conclusions
Given the continued rise of opioid use and prescribing rates among pregnant women
in Nevada, the incidence rates of NAS nearly doubled in 2016–2018, as compared to previ-
ous rates reported in 2013. However, a marginal downtrend of NAS incidence was observed
during the study period (2016–2018). Findings from this study have several important
implications for drug abuse treatment and prevention programs aimed at improving the
health outcomes of mother–infant dyads. A multifaceted approach including national-,
state-, and provider-level efforts is required to curb the NAS epidemic. Provider education
programs to emphasize responsible prescribing by limiting the number of days, dosage
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levels, prescribing alternative non-opioid pain relievers, and limiting access to refills can
be beneficial in reducing the neonatal impact of prenatal opioid use. More importantly,
mandated clinical reporting of Neonatal Abstinence Syndrome in Nevada is important
to direct rapid preventive efforts without the time-lag associated with reporting in health
insurance claim data. Clinical reporting would help document detailed maternal exposure
history and the type of addictive drug used in designing targeted interventions. This study
highlights the need for additional research examining the health and financial burden
associated with readmission rates and long-term complications of NAS to obtain a holistic
view of the problem and establish a continuum of care. It also emphasizes the need for
additional regional studies to explore the multidimensional spectrum in the rural–urban
context. Prospective studies to assess rate of use/adoption of PMPs by providers and
effectiveness of PMPs on opioid overprescribing rates can be a crucial step in controlling
the opioid epidemic and neonatal sequelae, such as NAS.
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